Osimertinib is a potent inhibitor of EGFR (60). Osimertinib was reported (unpublished results; preprint) to be one of 24 FDA-approved drugs to show in vitro activity against SARS-CoV-2 (0.1 μM<IC50<10 μM)) (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Osimertinib has been approved for non-small cell lung carcinoma (Table 2).